CN105603037A - Method for preparing cephalosporin through enzyme catalytic acylation - Google Patents
Method for preparing cephalosporin through enzyme catalytic acylation Download PDFInfo
- Publication number
- CN105603037A CN105603037A CN201510981431.5A CN201510981431A CN105603037A CN 105603037 A CN105603037 A CN 105603037A CN 201510981431 A CN201510981431 A CN 201510981431A CN 105603037 A CN105603037 A CN 105603037A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- acylation
- cynnematin
- reaction
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005917 acylation reaction Methods 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 68
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 45
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 45
- 230000010933 acylation Effects 0.000 title claims abstract description 26
- 229930186147 Cephalosporin Natural products 0.000 title abstract description 58
- 229940124587 cephalosporin Drugs 0.000 title abstract description 58
- 150000001780 cephalosporins Chemical class 0.000 title abstract description 58
- 230000003197 catalytic effect Effects 0.000 title abstract description 34
- 239000000047 product Substances 0.000 claims abstract description 64
- 239000000725 suspension Substances 0.000 claims abstract description 55
- 239000002002 slurry Substances 0.000 claims abstract description 41
- 230000008569 process Effects 0.000 claims abstract description 37
- 238000000926 separation method Methods 0.000 claims abstract description 25
- 239000000706 filtrate Substances 0.000 claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 238000007670 refining Methods 0.000 claims abstract description 4
- 150000003952 β-lactams Chemical group 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- -1 cefotaxime acid esters salt Chemical class 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 14
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 2
- 238000001238 wet grinding Methods 0.000 claims 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical class N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 12
- 230000009471 action Effects 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000003912 environmental pollution Methods 0.000 abstract description 3
- 125000003460 beta-lactamyl group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 41
- 239000003795 chemical substances by application Substances 0.000 description 26
- 108010073038 Penicillin Amidase Proteins 0.000 description 16
- 239000012065 filter cake Substances 0.000 description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- DTHMTBUWTGVEFG-QRPNPIFTSA-N [(1s)-2-methoxy-2-oxo-1-phenylethyl]azanium;chloride Chemical compound Cl.COC(=O)[C@@H](N)C1=CC=CC=C1 DTHMTBUWTGVEFG-QRPNPIFTSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 4
- 229960005361 cefaclor Drugs 0.000 description 4
- 229960004841 cefadroxil Drugs 0.000 description 4
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 4
- 229960004261 cefotaxime Drugs 0.000 description 4
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 4
- 229960002588 cefradine Drugs 0.000 description 4
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 4
- 229940106164 cephalexin Drugs 0.000 description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- YMBMCMOZIGSBOA-UHFFFAOYSA-N ethyl 2-amino-2-sulfanylideneacetate Chemical group CCOC(=O)C(N)=S YMBMCMOZIGSBOA-UHFFFAOYSA-N 0.000 description 3
- UYCKVJUNDXPDJH-DDWIOCJRSA-N methyl (2r)-2-amino-2-(4-hydroxyphenyl)acetate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)C1=CC=C(O)C=C1 UYCKVJUNDXPDJH-DDWIOCJRSA-N 0.000 description 3
- VOUGEZYPVGAPBB-UHFFFAOYSA-N penicillin acid Natural products OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 description 3
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- SZBDOFWNZVHVGR-MRVPVSSYSA-N methyl (2r)-2-amino-2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)[C@H](N)C1=CC=C(O)C=C1 SZBDOFWNZVHVGR-MRVPVSSYSA-N 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- FNNXQLSKQSVNLL-SBSPUUFOSA-N ethyl (2r)-2-amino-2-phenylacetate;hydrochloride Chemical compound Cl.CCOC(=O)[C@H](N)C1=CC=CC=C1 FNNXQLSKQSVNLL-SBSPUUFOSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
- C12P35/04—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin by acylation of the substituent in the 7 position
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cephalosporin Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种酶催化酰化制备头孢菌素的方法,包括:A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆;B.震荡分离,控制产物料浆黏度,采用振荡筛,在一定工艺条件下对产物料浆进行震荡分离,得到催化酶滤渣和头孢菌素混悬滤液;C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉,经洗涤、干燥,得精制产物。本发明通过优化工艺流程及工艺参数,解决了现有工艺存在的酶分离困难、制备成本高,环境污染严重等问题,在够保证产品质量的同时,简化了工艺流程、提高了分离效率和生产效率、降低了生产成本。The invention relates to a method for preparing cephalosporins by enzyme-catalyzed acylation, comprising: A. acylation reaction, performing acylation reaction with an acylation reagent and a β-lactam core under the action of a catalytic enzyme to obtain a product slurry; B. Vibration separation, control the viscosity of the product slurry, use a vibrating sieve to vibrate and separate the product slurry under certain process conditions, and obtain the catalytic enzyme filter residue and cephalosporin suspension filtrate; C. Refining the product, mixing the cephalosporin The suspension filtrate was filtered to obtain wet powder of cephalosporin, which was washed and dried to obtain a refined product. By optimizing the process flow and process parameters, the present invention solves the problems of difficult enzyme separation, high preparation cost, and serious environmental pollution in the existing process. While ensuring product quality, it simplifies the process flow, improves separation efficiency and production efficiency. efficiency and reduce production costs.
Description
技术领域 technical field
本发明涉及抗生素合成技术领域,尤其是一种头孢菌素的新型制备方法。 The invention relates to the technical field of antibiotic synthesis, in particular to a novel preparation method of cephalosporins.
背景技术 Background technique
头孢菌素(cephalosporins)是以冠头孢菌培养得到的天然头孢菌素C作为原料,经半合成改造其侧链而得到的分子中含有头孢烯的半合成抗生素,具有相似的杀菌机制。本类药可破坏细菌的细胞壁,并在繁殖期杀菌。对细菌的选择作用强,而对人几乎没有毒性,具有抗菌谱广、抗菌作用强、耐青霉素酶、过敏反应较青霉素类少见等优点。所以是一类高效、低毒、临床广泛应用的重要抗生素。 Cephalosporins (cephalosporins) is a semi-synthetic antibiotic containing cephem in the molecule obtained by semi-synthetic modification of the side chain of the natural cephalosporin C obtained from the culture of Cephalosporus coronaris, which has a similar bactericidal mechanism. This class of drugs can destroy the cell wall of bacteria and kill bacteria during the reproduction period. It has a strong selective effect on bacteria, but has almost no toxicity to humans. It has the advantages of broad antibacterial spectrum, strong antibacterial effect, penicillinase resistance, and allergic reactions are rare compared with penicillins. Therefore, it is an important antibiotic with high efficiency, low toxicity and wide clinical application.
目前,头孢菌素的合成绿色工艺为酶法,这一工艺已被专利文献广泛描述。与传统的化学方法相比较,酶法合成无论从降低成本、简化工艺,还是从环境友好等方面考虑,都具有明显优势。但其仍有许多不尽人意之处,如:现有酶法合成头孢菌素的工艺其酶缩合反应过程中存在较严重的酶分离困难,为此专利文献CN203569090U针对酶分离过程进行了阐述。另外,目前报道的专利文献,如专利文献CN103805671B、专利文献CN102656274A,其生产过程都有重结晶,操作较为繁琐。 Currently, the green process for the synthesis of cephalosporins is enzymatic, and this process has been extensively described in patent literature. Compared with traditional chemical methods, enzymatic synthesis has obvious advantages in terms of cost reduction, process simplification, and environmental friendliness. But it still has many unsatisfactory parts, such as: there are more serious enzyme separation difficulties in the enzymatic condensation reaction process of the process of the existing enzymatic synthesis of cephalosporins, for this reason the patent document CN203569090U elaborates on the enzyme separation process. In addition, currently reported patent documents, such as patent document CN103805671B and patent document CN102656274A, have recrystallization in the production process, and the operation is relatively cumbersome.
因此,亟需对头孢菌素的酶法合成工艺进行改进,简化工艺流程、提高分离效率和生产效率。 Therefore, it is urgent to improve the enzymatic synthesis process of cephalosporins, simplify the process flow, and improve the separation efficiency and production efficiency.
发明内容 Contents of the invention
本发明需要解决的技术问题是提供一种酶催化酰化制备头孢菌素的方法,以解决现有工艺存在的酶分离困难、制备成本高,环境污染严重等问题,简化工艺流程、提高分离效率和生产效率。 The technical problem to be solved in the present invention is to provide a method for preparing cephalosporins by enzyme-catalyzed acylation, so as to solve the problems of difficult enzyme separation, high preparation cost and serious environmental pollution in the existing technology, simplify the process flow and improve the separation efficiency and production efficiency.
为解决上述技术问题,本发明所采用的技术方案是: In order to solve the problems of the technologies described above, the technical solution adopted in the present invention is:
一种酶催化酰化制备头孢菌素的方法,所述方法包括以下步骤, A method for preparing cephalosporins by enzyme-catalyzed acylation, said method comprising the following steps,
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆; A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry;
B.震荡分离,控制产物料浆黏度,采用振荡筛,在一定工艺条件下对产物料浆进行震荡分离,得到催化酶滤渣和头孢菌素混悬滤液; B. Vibration separation, control the viscosity of the product slurry, use a vibrating sieve to vibrate and separate the product slurry under certain process conditions, and obtain the catalytic enzyme filter residue and cephalosporin suspension filtrate;
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉,经洗涤、干燥,得精制产物。 C. Refining the product, filtering the suspension filtrate of the cephalosporin to obtain wet powder of the cephalosporin, washing and drying to obtain the refined product.
本发明技术方案的进一步改进在于:所述步骤A的具体过程为,将酰化试剂在一定时间内缓慢加入到β-内酰胺核的水溶液中,控制β-内酰胺核水溶液pH,然后加入催化酶,在一定温度下进行酰化反应,反应过程中控制酰化反应pH,酰化反应一定时间后得到产物浆料。 The further improvement of the technical solution of the present invention lies in: the specific process of the step A is that the acylating agent is slowly added to the aqueous solution of the β-lactam nucleus within a certain period of time, the pH of the aqueous solution of the β-lactam nucleus is controlled, and then the catalytic The enzyme performs the acylation reaction at a certain temperature, controls the pH of the acylation reaction during the reaction process, and obtains a product slurry after the acylation reaction for a certain period of time.
本发明技术方案的进一步改进在于:所述步骤A中,酰化试剂与β-内酰胺核的摩尔比为1.05:1~1.2:1,催化酶与照β-内酰胺核的质量比为0.3:1~2:1,β-内酰胺核水溶液的质量浓度为30~60%,β-内酰胺核水溶液pH为6.5~8.5,酰化反应pH为6.0~7.2,酰化反应温度为15~25℃,酰化试剂的加料时间为30~120min。 The further improvement of the technical solution of the present invention is: in the step A, the molar ratio of the acylating agent to the β-lactam core is 1.05:1 to 1.2:1, and the mass ratio of the catalytic enzyme to the β-lactam core is 0.3 :1~2:1, the mass concentration of β-lactam nucleus aqueous solution is 30~60%, the pH of β-lactam nucleus aqueous solution is 6.5~8.5, the acylation reaction pH is 6.0~7.2, and the acylation reaction temperature is 15~ At 25°C, the feeding time of the acylating reagent is 30-120 minutes.
本发明技术方案的进一步改进在于:所述步骤A的酰化反应过程中,通过氨水控制酰化反应pH,从开始反应至反应液出现浑浊的时间记为t,当反应时间为2t~3t时,向反应液中缓慢加入水,加入的水与反应液的体积比为0.3:1~0.5:1;加入水的过程用时20~60min,在加水的过程中用HPLC法判断反应终点。 The further improvement of the technical solution of the present invention is: during the acylation reaction process of the step A, the pH of the acylation reaction is controlled by ammonia water, and the time from the start of the reaction to the turbidity of the reaction solution is recorded as t, when the reaction time is 2t ~ 3t , slowly add water to the reaction solution, the volume ratio of the added water to the reaction solution is 0.3:1-0.5:1; the process of adding water takes 20-60 minutes, and the HPLC method is used to judge the reaction end point during the process of adding water.
本发明技术方案的进一步改进在于:所述步骤A中,酰化试剂为D-苯甘氨酸酯、D-苯甘氨酸酯盐、D-苯甘氨酸酯的衍生物、D-苯甘氨酸酯的衍生物盐、氨噻肟酸酯、氨噻肟酸酯盐的其中一种。 The further improvement of the technical solution of the present invention is: in the step A, the acylating agent is D-phenylglycine ester, D-phenylglycine ester salt, derivative of D-phenylglycine ester, derivative salt of D-phenylglycine ester , one of aminothioxamate and aminothioxate salts.
本发明技术方案的进一步改进在于:所述步骤A中,β-内酰胺核为青霉素酸衍生物、头孢菌素酸衍生物的其中一种。 The further improvement of the technical solution of the present invention lies in that: in the step A, the β-lactam nucleus is one of penicillin acid derivatives and cephalosporin acid derivatives.
本发明技术方案的进一步改进在于:所述步骤A中,催化酶为青霉素酰化酶。 The further improvement of the technical solution of the present invention lies in: in the step A, the catalytic enzyme is penicillin acylase.
本发明技术方案的进一步改进在于:所述步骤B中,产物浆料黏度控制在10~400mPa·s,振荡筛的过滤筛网80~120目,振荡筛的振频为1000~3000rpm。 The further improvement of the technical solution of the present invention lies in: in the step B, the viscosity of the product slurry is controlled at 10-400 mPa·s, the filter mesh of the vibrating screen is 80-120 mesh, and the vibration frequency of the vibrating screen is 1000-3000 rpm.
本发明技术方案的进一步改进在于:所述步骤C中,洗涤头孢菌素湿粉的溶剂为水、丙酮、乙醇的其中一种或几种,干燥温度为30~50℃。 The further improvement of the technical solution of the present invention is: in the step C, the solvent for washing the wet cephalosporin powder is one or more of water, acetone, and ethanol, and the drying temperature is 30-50°C.
由于采用了上述技术方案,本发明取得的技术进步是: Owing to having adopted above-mentioned technical scheme, the technical progress that the present invention obtains is:
本发明的一种酶催化酰化制备头孢菌素的方法,通过优化工艺流程及工艺参数,解决了现有工艺存在的酶分离困难、制备成本高,环境污染严重等问题,在够保证产品质量的同时,简化了工艺流程、提高了分离效率和生产效率、降低了生产成本。 A method for preparing cephalosporins by enzyme-catalyzed acylation of the present invention solves the problems of difficult enzyme separation, high preparation costs, and serious environmental pollution in the existing process by optimizing the process flow and process parameters, and can ensure product quality. At the same time, the process flow is simplified, the separation efficiency and production efficiency are improved, and the production cost is reduced.
本发明通过控制酰化反应的工艺条件,提高了酰化反应的转化率,减少了副产物的产生,降低了产物料浆成分的复杂程度,为后续分离工艺奠定了良好的基础。 By controlling the process conditions of the acylation reaction, the invention improves the conversion rate of the acylation reaction, reduces the generation of by-products, reduces the complexity of product slurry components, and lays a good foundation for the subsequent separation process.
本发明通过对产物料浆的特性进行分析,控制好产物料浆黏度,创造性地使用振荡筛对产物浆料中的成分进行分离,解决了传统工艺中纯化困难的问题,能够以将产物料浆分离成催化酶滤渣和头孢菌素混悬滤液,且头孢菌素混悬滤液产品不需要经重结晶步骤,只需简单的洗涤,就可得到符合药典要求的产品。极大地简化了工艺流程,提高了产品纯度。 The present invention analyzes the characteristics of the product slurry, controls the viscosity of the product slurry, creatively uses a vibrating screen to separate the components in the product slurry, solves the problem of difficult purification in the traditional process, and can make the product slurry It is separated into catalytic enzyme filter residue and cephalosporin suspension filtrate, and the cephalosporin suspension filtrate product does not need to go through a recrystallization step, and only needs simple washing to obtain a product that meets the requirements of the Pharmacopoeia. The technological process is greatly simplified and the product purity is improved.
本发明的一种酶催化酰化制备头孢菌素的方法可被用于制备β-内酰胺抗生素,例如头孢氨苄、头孢羟氨苄、头孢克洛、青霉素氨苄、阿莫西林、头孢拉定、头孢噻肟等的生产。 A method for preparing cephalosporins by enzymatic acylation of the present invention can be used to prepare β-lactam antibiotics, such as cephalexin, cefadroxil, cefaclor, penicillin ampicillin, amoxicillin, cephradine, cefotaxime etc. production.
具体实施方式 detailed description
本发明公开了一种酶催化酰化制备头孢菌素的方法,包括以下步骤: The invention discloses a method for preparing cephalosporins by enzyme-catalyzed acylation, which comprises the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry.
步骤A的具体过程为,将酰化试剂在一定时间内缓慢加入到β-内酰胺核的水溶液中,控制β-内酰胺核水溶液pH,然后加入催化酶,在一定温度下进行酰化反应,反应过程中控制酰化反应pH,酰化反应一定时间后得到产物浆料。 The specific process of step A is that the acylating agent is slowly added to the aqueous solution of the β-lactam nucleus within a certain period of time, the pH of the aqueous solution of the β-lactam nucleus is controlled, and then a catalytic enzyme is added to carry out the acylation reaction at a certain temperature. During the reaction process, the pH of the acylation reaction is controlled, and the product slurry is obtained after the acylation reaction for a certain period of time.
其中,酰化试剂与β-内酰胺核的摩尔比为1.05:1~1.2:1,催化酶与照β-内酰胺核的质量比为0.3:1~2:1。β-内酰胺核水溶液的质量浓度为30~60%,β-内酰胺核水溶液pH为6.0~8.5,优选为7.8~8.0。酰化反应pH为6.0~7.2,优选为6.5~7.0。酰化反应温度为15~25℃,酰化试剂的加料时间为30~120min。 Wherein, the molar ratio of the acylating agent to the β-lactam nucleus is 1.05:1-1.2:1, and the mass ratio of the catalytic enzyme to the β-lactam nucleus is 0.3:1-2:1. The mass concentration of the β-lactam nucleus aqueous solution is 30-60%, and the pH of the β-lactam nucleus aqueous solution is 6.0-8.5, preferably 7.8-8.0. The pH of the acylation reaction is 6.0-7.2, preferably 6.5-7.0. The acylation reaction temperature is 15-25° C., and the feeding time of the acylating reagent is 30-120 minutes.
酰化反应过程中,通过氨水控制酰化反应pH,用HPLC法判断反应终点。 During the acylation reaction, the pH of the acylation reaction was controlled by ammonia water, and the reaction end point was judged by HPLC.
具体地,酰化试剂为D-苯甘氨酸酯、D-苯甘氨酸酯盐、D-苯甘氨酸酯的衍生物、D-苯甘氨酸酯的衍生物盐、氨噻肟酸酯、氨噻肟酸酯盐的其中一种。 Specifically, the acylating agent is one of D-phenylglycine ester, D-phenylglycine ester salt, D-phenylglycine ester derivative, D-phenylglycine ester derivative salt, aminothioxate, and aminothioxate salt.
优选地,当酰化试剂为D-苯甘氨酸酯的衍生物时,可以是D-对羟基苯甘氨酸酯、D-双氢苯甘氨酸酯。当酰化试剂为氨噻肟酸酯时,是氨噻肟酸乙酯。 Preferably, when the acylating agent is a derivative of D-phenylglycine ester, it may be D-p-hydroxyphenylglycine ester or D-dihydrophenylglycine ester. When the acylating agent is thioxamate, it is ethyl thioxamate.
进一步地优选,酰化试剂优选为D-苯甘氨酸酯盐以及D-苯甘氨酸酯的衍生物盐,成盐试剂优选盐酸、硫酸,形成盐酸盐、硫酸盐,具体为:D-苯甘氨酸甲酯盐酸盐、D-苯甘氨酸乙酯盐酸盐、D-对羟基苯甘氨酸甲酯盐酸盐、D-双苯甘氨酸甲酯盐酸盐、D-苯甘氨酸甲酯硫酸盐、D-苯甘氨酸乙酯硫酸盐,D-对羟基苯甘氨酸甲酯硫酸盐、D-双氢苯甘氨酸甲酯硫酸盐、氨噻肟酸乙酯盐酸盐。 Further preferably, the acylating agent is preferably D-phenylglycine ester salt and derivative salt of D-phenylglycine ester, and the salt-forming agent is preferably hydrochloric acid or sulfuric acid to form hydrochloride and sulfate, specifically: D-phenylglycine methyl Ester hydrochloride, D-phenylglycine ethyl ester hydrochloride, D-p-hydroxyphenylglycine methyl ester hydrochloride, D-bisphenylglycine methyl ester hydrochloride, D-phenylglycine methyl sulfate, D-benzene Glycine ethyl sulfate, D-hydroxyphenylglycine methyl sulfate, D-dihydrophenylglycine methyl sulfate, aminothioxamic acid ethyl ester hydrochloride.
酰化试剂的试剂类型进一步地优选为:固体颗粒、溶液或混悬液。 The reagent type of the acylating reagent is further preferably: solid particle, solution or suspension.
具体地,β-内酰胺核为青霉素酸衍生物、头孢菌素酸衍生物的其中一种。 Specifically, the β-lactam core is one of penicillin acid derivatives and cephalosporin acid derivatives.
优选地,β-内酰胺核可以是各种青霉素酸衍生物,例如6-氨基青霉素酸(6-APA);β-内酰胺核可以是各种头孢菌素酸衍生物,例如7-氨基头孢菌素酸(7-ACA)、7-氨基去乙酰氧基头孢菌素酸(7-ADCA)和7-氨基-3-氯头孢菌素酸(7-ACCA)。 Preferably, the β-lactam core can be various penicillin acid derivatives, such as 6-aminopenicillin acid (6-APA); the β-lactam core can be various cephalosporin acid derivatives, such as 7-aminocephalosporin Acidic acid (7-ACA), 7-aminodesacetoxycephalosporinic acid (7-ADCA) and 7-amino-3-chlorocephalosporinic acid (7-ACCA).
具体地,催化酶为青霉素酰化酶。 Specifically, the catalytic enzyme is penicillin acylase.
B.震荡分离,控制产物料浆黏度,采用振荡筛,在一定工艺条件下对产物料浆进行震荡分离,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillating separation, controlling the viscosity of the product slurry, using a vibrating sieve, and vibrating and separating the product slurry under certain process conditions to obtain catalytic enzyme filter residue and cephalosporin suspension filtrate.
步骤B中,产物浆料黏度控制在10~400mPa·s,优选为100~300mPa·s,振荡筛的过滤筛网80~120目,振荡筛的振频为1000~3000rpm,优选2000~2500rpm。 In step B, the viscosity of the product slurry is controlled at 10-400 mPa·s, preferably 100-300 mPa·s, the filter screen of the vibrating screen is 80-120 mesh, and the vibration frequency of the vibrating screen is 1000-3000 rpm, preferably 2000-2500 rpm.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉,经洗涤、干燥,得精制产物。 C. Refining the product, filtering the suspension filtrate of the cephalosporin to obtain wet powder of the cephalosporin, washing and drying to obtain the refined product.
所述步骤C中,洗涤头孢菌素湿粉的溶剂为水、丙酮、乙醇的其中一种或几种,真空干燥温度为30~50℃。 In the step C, the solvent for washing the wet cephalosporin powder is one or more of water, acetone and ethanol, and the vacuum drying temperature is 30-50°C.
本发明的一种酶催化酰化制备头孢菌素的方法可被用于制备β-内酰胺抗生素,例如头孢氨苄、头孢羟氨苄、头孢克洛、青霉素氨苄、阿莫西林、头孢拉定、头孢噻肟等的生产。 A method for preparing cephalosporins by enzymatic acylation of the present invention can be used to prepare β-lactam antibiotics, such as cephalexin, cefadroxil, cefaclor, penicillin ampicillin, amoxicillin, cephradine, cefotaxime etc. production.
下面结合实施例对本发明做进一步详细说明: Below in conjunction with embodiment the present invention is described in further detail:
实施例1 Example 1
本实施例的酶催化酰化制备头孢菌素的方法,用于制备头孢氨苄。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing cephalexin.
本实施例中,选用的原料具体如下:酰化试剂选择D-苯甘氨酸甲酯盐酸盐固体,β-内酰胺核选择7-氨基去乙酰氧基头孢菌素酸(7-ADCA),催化酶选择青霉素酰化酶。 In the present embodiment, the selected raw materials are as follows: the acylating agent selects D-phenylglycine methyl ester hydrochloride solid, the β-lactam core selects 7-aminodesacetoxycephalosporin acid (7-ADCA), and the catalyst Enzyme selection Penicillin acylase.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入60Kg(约0.2800mol)的7-ADCA,加水80L,调节pH在8.0±0.2,得到质量浓度为75%的7-ADCA混悬溶液,然后向7-ADCA混悬溶液中加入30Kg的青霉素酰化酶,再在60min时间内向7-ADCA混悬溶液中缓慢加入63Kg(约0.3124mol)的D-苯甘氨酸甲酯盐酸盐固体,在20±1℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在7.0±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 60Kg (about 0.2800mol) of 7-ADCA in the reaction tank, add 80L of water, adjust the pH at 8.0 ± 0.2, obtain a 7-ADCA suspension solution with a mass concentration of 75%, and then mix it with 7-ADCA Add 30Kg of penicillin acylase to the suspension solution, then slowly add 63Kg (about 0.3124mol) of D-phenylglycine methyl ester hydrochloride solid to the 7-ADCA suspension solution within 60 minutes, and carry out at 20±1°C For the acylation reaction, ammonia water was used to control the pH of the acylation reaction at 7.0 ± 0.1 during the reaction, and the reaction liquid was a suspension throughout, and the reaction end point was judged by HPLC.
B.震荡分离,控制产物料浆黏度在250±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、振荡筛的振频为2500rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillation separation, control the viscosity of the product slurry at 250±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate and separate the product slurry under the technological conditions of 20±2°C and the vibration frequency of the vibrating screen at 2500rpm , after shaking and separating for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用50L水洗涤一次,再分别用50L丙酮洗涤两次,在40±2℃下干燥,得头孢氨苄90Kg,重量收率为150%,经测定纯度为99.9%。 C. the product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 50L water, then twice with 50L acetone, and dried at 40 ± 2°C. 90Kg of cephalexin was obtained, the weight yield was 150%, and the measured purity was 99.9%.
实施例2 Example 2
本实施例的酶催化酰化制备头孢菌素的方法,用于制备头孢羟氨苄。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing cefadroxil.
本实施例中,选用的原料具体如下:酰化试剂选择D-对羟基苯甘氨酸甲酯盐酸盐固体,β-内酰胺核选择7-氨基去乙酰氧基头孢菌素酸(7-ADCA),催化酶选择青霉素酰化酶。 In this embodiment, the selected raw materials are as follows: the acylating agent is selected from D-p-hydroxyphenylglycine methyl ester hydrochloride solid, and the β-lactam nucleus is selected from 7-aminodesacetoxycephalosporin acid (7-ADCA) , The catalytic enzyme selects penicillin acylase.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入60Kg(约0.2800mol)的7-ADCA,加水80L,调节pH在7.5±0.2,得到质量浓度为75%的7-ADCA混悬溶液,然后向7-ADCA混悬溶液中加入30Kg的青霉素酰化酶,再在60min时间内向7-ADCA混悬溶液中缓慢加入65Kg(约0.2986mol)的D-对羟基苯甘氨酸甲酯盐酸盐固体,在20±1℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在6.8±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 60Kg (about 0.2800mol) of 7-ADCA in the reaction tank, add 80L of water, adjust the pH at 7.5 ± 0.2, obtain a 7-ADCA suspension solution with a mass concentration of 75%, and then mix it with 7-ADCA Add 30Kg of penicillin acylase to the suspension solution, and then slowly add 65Kg (about 0.2986mol) of D-p-hydroxyphenylglycine methyl ester hydrochloride solid to the 7-ADCA suspension solution within 60min, at 20±1℃ The acylation reaction was carried out under the following conditions. During the reaction, ammonia water was used to control the pH of the acylation reaction at 6.8 ± 0.1. The reaction solution was a suspension from beginning to end. The end point of the reaction was judged by HPLC.
B.震荡分离,控制产物料浆黏度在200±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、振荡筛的振频为2000rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillation separation, control the viscosity of the product slurry at 200±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate and separate the product slurry under the technological conditions of 20±2°C and the vibration frequency of the vibrating screen at 2000rpm , after shaking and separating for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用50L水洗涤一次,再分别用50L丙酮洗涤两次,在40±2℃下干燥,得头孢羟氨苄90Kg,重量收率为150%,经测定纯度为99.9%。 C. the product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 50L water, then twice with 50L acetone, and dried at 40 ± 2°C. 90Kg of cefadroxil was obtained, the weight yield was 150%, and the measured purity was 99.9%.
实施例3 Example 3
本实施例的酶催化酰化制备头孢菌素的方法,用于制备阿莫西林。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing amoxicillin.
本实施例中,选用的原料具体如下:酰化试剂选择D-对羟基苯甘氨酸甲酯固体,β-内酰胺核选择6-氨基青霉素酸(6-APA),催化酶选择青霉素酰化酶。 In this embodiment, the selected raw materials are as follows: solid D-p-hydroxyphenylglycine methyl ester is selected as the acylating agent, 6-aminopenicillinic acid (6-APA) is selected as the β-lactam nucleus, and penicillin acylase is selected as the catalytic enzyme.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入60Kg(约0.2778mol)的6-APA,加水100L,调节pH在7.0±0.1,得到质量浓度为60%的6-APA混悬溶液,然后向6-APA混悬溶液加入30Kg的青霉素酰化酶,再在50min时间内向6-APA混悬溶液中缓慢加入54Kg(约0.2986mol)的D-对羟基苯甘氨酸甲酯固体,在20±1℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在6.5±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 60Kg (about 0.2778mol) of 6-APA in the reaction tank, add 100L of water, adjust the pH at 7.0 ± 0.1, obtain a 6-APA suspension solution with a mass concentration of 60%, and then mix it with 6-APA Add 30Kg of penicillin acylase to the suspension solution, then slowly add 54Kg (about 0.2986mol) of D-p-hydroxyphenylglycine methyl ester solid to the 6-APA suspension solution within 50 minutes, and carry out acylation at 20±1°C During the reaction, ammonia water is used to control the pH of the acylation reaction at 6.5 ± 0.1, the reaction solution is a suspension from beginning to end, and the end point of the reaction is judged by HPLC.
B.震荡分离,控制产物料浆黏度在300±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、振荡筛的振频为3000rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillation separation, control the viscosity of the product slurry at 300±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate and separate the product slurry under the technological conditions of 20±2°C and the vibration frequency of the vibrating screen at 3000rpm , after shaking and separating for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用30L水洗涤一次,再分别用50L乙醇洗涤两次,在40±2℃下干燥,得阿莫西林99Kg,重量收率为165%,经测定纯度为99.9%。 C. The product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 30L water, then twice with 50L ethanol, and dried at 40 ± 2°C. 99Kg of amoxicillin was obtained, the weight yield was 165%, and the measured purity was 99.9%.
实施例4 Example 4
本实施例的酶催化酰化制备头孢菌素的方法,用于制备头孢克洛。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing cefaclor.
本实施例中,选用的原料具体如下:酰化试剂选择D-苯甘氨酸甲酯盐酸盐,β-内酰胺核选择7-氨基-3-氯头孢菌素酸(7-ACCA),催化酶选择青霉素酰化酶。 In the present embodiment, the selected raw materials are as follows: the acylating agent selects D-phenylglycine methyl ester hydrochloride, the β-lactam nucleus selects 7-amino-3-chlorocephalosporin acid (7-ACCA), and the catalytic enzyme Select penicillin acylase.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入60Kg(约0.2557mol)的7-ACCA,加水80L,调节pH在8.0±0.2,得到质量浓度为75%的7-ACCA混悬溶液,然后向7-ACCA混悬溶液中加入60Kg的青霉素酰化酶,再在90min时间内向7-ACCA混悬溶液中缓慢加入58Kg(约0.2886mol)的D-苯甘氨酸甲酯盐酸盐固体,在20±1℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在7.0±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 60Kg (about 0.2557mol) of 7-ACCA in the reaction tank, add 80L of water, adjust the pH at 8.0 ± 0.2, obtain a 7-ACCA suspension solution with a mass concentration of 75%, and then mix it with 7-ACCA Add 60Kg of penicillin acylase to the suspension solution, and then slowly add 58Kg (about 0.2886mol) of D-phenylglycine methyl ester hydrochloride solid to the 7-ACCA suspension solution within 90 minutes at 20±1°C For the acylation reaction, ammonia water was used to control the pH of the acylation reaction at 7.0 ± 0.1 during the reaction, and the reaction liquid was a suspension throughout, and the reaction end point was judged by HPLC.
B.震荡分离,控制产物料浆黏度在100±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、振荡筛的振频为1000rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillation separation, control the viscosity of the product slurry at 100±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate and separate the product slurry under the technological conditions of 20±2°C and the vibration frequency of the vibrating screen at 1000rpm , after shaking and separating for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用10L水洗涤一次,再分别用20L丙酮洗涤两次,在45±2℃下干燥,得头孢克洛87Kg,重量收率为145%%,经测定纯度为99.9%。 C. The product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 10L water, then twice with 20L acetone, and dried at 45 ± 2°C. 87Kg of cefaclor was obtained, the weight yield was 145%, and the measured purity was 99.9%.
实施例5 Example 5
本实施例的酶催化酰化制备头孢菌素的方法,用于制备青霉素氨苄。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for the preparation of penicillin ampicillin.
本实施例中,选用的原料具体如下:酰化试剂选择D-苯甘氨酸甲酯盐酸盐,β-内酰胺核选择6-氨基青霉素酸(6-APA),催化酶选择青霉素酰化酶。 In this example, the selected raw materials are as follows: D-phenylglycine methyl ester hydrochloride was selected as the acylating agent, 6-aminopenicillinic acid (6-APA) was selected as the β-lactam nucleus, and penicillin acylase was selected as the catalytic enzyme.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入10Kg(约0.046mol)的6-APA,加水25L,调节pH在8.0±0.2,得到质量浓度为40%的6-APA混悬溶液。然后向6-APA混悬溶液中加入5Kg的青霉素酰化酶。将9.6Kg(约0.048mol)的D-苯甘氨酸甲酯盐酸盐加入15L水溶液中溶解。再在90min时间内将D-苯甘氨酸甲酯盐酸盐溶解液缓慢加入到6-APA混悬溶液中,在20±1℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在7.0±0.2,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is as follows: add 10Kg (about 0.046mol) of 6-APA into the reaction tank, add 25L of water, adjust the pH at 8.0±0.2, and obtain a 6-APA suspension solution with a mass concentration of 40%. Then add 5Kg of penicillin acylase to the 6-APA suspension solution. Add 9.6Kg (about 0.048mol) of D-phenylglycine methyl ester hydrochloride into 15L aqueous solution to dissolve. Then slowly add the D-phenylglycine methyl ester hydrochloride solution into the 6-APA suspension solution within 90 minutes, and carry out the acylation reaction at 20±1°C. During the reaction, the pH of the acylation reaction is controlled by ammonia water. 7.0 ± 0.2, the reaction solution is a suspension from beginning to end, and the reaction end point is judged by HPLC method.
B.震荡分离,控制产物料浆黏度在200±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、、振荡筛的振频为2000rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Vibration separation, control the viscosity of the product slurry at 200±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate the product slurry at 20±2°C, and the vibrating frequency of the vibrating screen is 2000rpm Separation, shaking and separation for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用5L水洗涤一次,再分别用10L丙酮洗涤两次,在40±2℃下干燥,得青霉素氨苄16.68Kg,重量收率166.8%,经测定纯度为99.9%。 C. The product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 5L water, then twice with 10L acetone, and dried at 40 ± 2°C. Penicillin ampicillin 16.68Kg was obtained, the weight yield was 166.8%, and the determined purity was 99.9%.
实施例6 Example 6
本实施例的酶催化酰化制备头孢菌素的方法,用于制备头孢拉定。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing cephradine.
本实施例中,选用的原料具体如下:酰化试剂选择D-双氢苯甘氨酸甲酯盐酸盐,β-内酰胺核选择7-氨基去乙酰氧基头孢菌素酸(7-ADCA),催化酶选择青霉素酰化酶。 In this embodiment, the selected raw materials are as follows: the acylating agent is selected from D-dihydrophenylglycine methyl ester hydrochloride, the β-lactam nucleus is selected from 7-aminodesacetoxycephalosporin acid (7-ADCA), Catalytic enzyme selection penicillin acylase.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入60Kg(约0.2804mol)的7-ADCA,加水120L,调节pH在8.0±0.2,得到质量浓度为50%的7-ADCA混悬溶液,然后向7-ADCA混悬溶液加入60Kg的青霉素酰化酶。将64.9Kg(约0.3197mol)的D-双氢苯甘氨酸甲酯盐酸盐加入到90L水中溶解。再在60min时间内将D-双氢苯甘氨酸甲酯盐酸盐的溶液缓慢加入到7-ADCA混悬溶液中,在20±2℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在6.8±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 60Kg (about 0.2804mol) of 7-ADCA in the reaction tank, add 120L of water, adjust the pH at 8.0 ± 0.2, obtain a 7-ADCA suspension solution with a mass concentration of 50%, and then mix it with 7-ADCA Add 60Kg of penicillin acylase to the suspension solution. Add 64.9Kg (about 0.3197mol) of D-dihydrophenylglycine methyl ester hydrochloride into 90L of water to dissolve. Then slowly add the solution of D-dihydrophenylglycine methyl ester hydrochloride into the 7-ADCA suspension solution within 60 minutes, and carry out the acylation reaction at 20±2°C, and use ammonia water to control the acylation reaction during the reaction The pH is 6.8±0.1, the reaction solution is a suspension throughout, and the reaction end point is judged by HPLC.
B.震荡分离,控制产物料浆黏度在280±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、振荡筛的振频为2800rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Oscillation separation, control the viscosity of the product slurry at 280±20mPa s, use the filter screen as a 100-mesh vibrating sieve, and vibrate and separate the product slurry under the technological conditions of 20±2°C and the vibration frequency of the vibrating screen at 2800rpm , after shaking and separating for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用10L水洗涤一次,再分别用20L丙酮洗涤两次,在40±2℃下干燥,得头孢拉定90Kg,重量收率150%,经测定纯度为99.9%。 C. The product is refined, and the cephalosporin suspension filtrate is filtered to obtain a cephalosporin wet powder filter cake. The filter cake is washed once with 10L water, then twice with 20L acetone, and dried at 40 ± 2°C. 90Kg of cephradine was obtained, the weight yield was 150%, and the measured purity was 99.9%.
实施例7 Example 7
本实施例的酶催化酰化制备头孢菌素的方法,用于制备头孢噻肟。 The method for preparing cephalosporins by enzyme-catalyzed acylation in this embodiment is used for preparing cefotaxime.
本实施例中,选用的原料具体如下:酰化试剂选择氨噻肟酸乙酯,β-内酰胺核选择7-氨基头孢烷酸(7-ACA),催化酶选择青霉素酰化酶。 In this embodiment, the selected raw materials are as follows: ethyl acetioxamate is selected as the acylating agent, 7-aminocephalosporanic acid (7-ACA) is selected as the β-lactam nucleus, and penicillin acylase is selected as the catalytic enzyme.
具体包括以下步骤: Specifically include the following steps:
A.酰化反应,将酰化试剂与β-内酰胺核在催化酶的作用下进行酰化反应,得到产物料浆。具体过程为,在反应罐中加入10Kg(约0.037mol)的7-ACA,加水20L,调节pH在8.0±0.2,得到质量浓度为50%的7-ACA混悬溶液,然后向7-ACA混悬溶液中加入10Kg的青霉素酰化酶。将10.8Kg(约0.044mol)的氨噻肟酸乙酯加入到20L水中溶解,再在90min时间内将氨噻肟酸乙酯的溶液缓慢加入到7-ACA混悬溶液中,在20±2℃下进行酰化反应,反应过程中用氨水控制酰化反应pH在6.5±0.1,反应液自始至终为混悬液,用HPLC法判断反应终点。 A. Acylation reaction, acylating the acylating agent and the β-lactam core under the action of a catalytic enzyme to obtain a product slurry. The specific process is, add 10Kg (about 0.037mol) of 7-ACA in the reaction tank, add 20L of water, adjust the pH at 8.0 ± 0.2, and obtain a 7-ACA suspension solution with a mass concentration of 50%, and then mix it with 7-ACA Add 10Kg of penicillin acylase to the suspension solution. Add 10.8Kg (about 0.044mol) of ethyl thioxamate to 20L of water to dissolve, then slowly add the solution of ethyl thioxamate to the 7-ACA suspension within 90 minutes, and carry out the acylation reaction at 20±2°C During the reaction process, ammonia water is used to control the pH of the acylation reaction at 6.5 ± 0.1, the reaction solution is a suspension throughout, and the reaction end point is judged by HPLC.
B.震荡分离,控制产物料浆黏度在300±20mPa·s,采用过滤筛网为100目的振荡筛,在20±2℃、、振荡筛的振频为3000rpm工艺条件下对产物料浆进行震荡分离,震荡分离1小时后,得到催化酶滤渣和头孢菌素混悬滤液。 B. Vibration separation, control the viscosity of the product slurry at 300±20mPa·s, use the filter screen as a 100-mesh vibrating sieve, and vibrate the product slurry at 20±2°C, and the vibrating frequency of the vibrating screen is 3000rpm Separation, shaking and separation for 1 hour, the catalytic enzyme filter residue and cephalosporin suspension filtrate were obtained.
C.产物精制,对头孢菌素混悬滤液进行过滤,得到头孢菌素湿粉滤饼,滤饼先用5L洗涤一次,再分别用10L丙酮洗涤两次,在45±2℃下干燥,得头孢噻肟14.3Kg,重量收率为143%,经测定纯度为99.9%。 C. the product is refined, and the cephalosporin suspension filtrate is filtered to obtain the cephalosporin wet powder filter cake. The filter cake is washed once with 5L, then washed twice with 10L acetone, and dried at 45 ± 2°C to obtain Cefotaxime 14.3Kg, the weight yield is 143%, and the determined purity is 99.9%.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981431.5A CN105603037B (en) | 2015-12-24 | 2015-12-24 | Method for preparing cephalosporin by enzymatic acylation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981431.5A CN105603037B (en) | 2015-12-24 | 2015-12-24 | Method for preparing cephalosporin by enzymatic acylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105603037A true CN105603037A (en) | 2016-05-25 |
| CN105603037B CN105603037B (en) | 2020-07-31 |
Family
ID=55983375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510981431.5A Active CN105603037B (en) | 2015-12-24 | 2015-12-24 | Method for preparing cephalosporin by enzymatic acylation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105603037B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058447A (en) * | 2016-12-23 | 2017-08-18 | 苏州中联化学制药有限公司 | A kind of method of enzymatic clarification cefadroxil |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997022610A1 (en) * | 1995-12-08 | 1997-06-26 | Gist-Brocades B.V. | Process for the preparation of an antibiotic |
| CN203569090U (en) * | 2013-10-17 | 2014-04-30 | 华北制药河北华民药业有限责任公司 | Reaction and separation device of enzymic-method cephalosporin products |
| CN103805671A (en) * | 2013-11-11 | 2014-05-21 | 华北制药河北华民药业有限责任公司 | Method for preparing cefalexin |
-
2015
- 2015-12-24 CN CN201510981431.5A patent/CN105603037B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997022610A1 (en) * | 1995-12-08 | 1997-06-26 | Gist-Brocades B.V. | Process for the preparation of an antibiotic |
| CN203569090U (en) * | 2013-10-17 | 2014-04-30 | 华北制药河北华民药业有限责任公司 | Reaction and separation device of enzymic-method cephalosporin products |
| CN103805671A (en) * | 2013-11-11 | 2014-05-21 | 华北制药河北华民药业有限责任公司 | Method for preparing cefalexin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058447A (en) * | 2016-12-23 | 2017-08-18 | 苏州中联化学制药有限公司 | A kind of method of enzymatic clarification cefadroxil |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105603037B (en) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101613359B (en) | Method for synthesizing cefuroxime sodium | |
| US8497088B2 (en) | Process for the preparation of beta-lactam compounds | |
| CN102725297A (en) | Process for preparation of cephalosporin derivative | |
| CN105603037B (en) | Method for preparing cephalosporin by enzymatic acylation | |
| WO2014072843A1 (en) | Process for preparing isoxazolyl penicillins | |
| CN107058447A (en) | A kind of method of enzymatic clarification cefadroxil | |
| JP5022913B2 (en) | Method for synthesizing cefaclor | |
| CN102167705A (en) | Preparation method of cefmenoxime hydrochloride | |
| CN107445978A (en) | A kind of synthesis of cefalonium and purification process | |
| EP1023454B1 (en) | Process for the preparation of a (beta)-lactam antibiotic | |
| CN106432134B (en) | The method of purification of No. 7 position pendant reactive esters of cynnematin | |
| CN101130803B (en) | A method for enzymatically synthesizing β-lactam antibiotics in organic solvents | |
| CN103833772B (en) | A kind of synthetic method of cephalosporin | |
| CN104230955B (en) | A kind of preparation method to the acid of hydroxyl penicillin V and salt thereof | |
| KR20010043038A (en) | A METHOD FOR CRYSTALLIZING A β-LACTAM ANTIBIOTIC | |
| JPH11503408A (en) | How to recover cephalexin | |
| CN103108879B (en) | Process for producing cephalosporins | |
| CN102850380B (en) | Preparation method of cefodizime acid | |
| CN102584853B (en) | Preparation method of 7-aminodeacetoxy cephalosporanic acid | |
| JPH08256789A (en) | Enzymatic synthesis in the presence of enzyme inhibitors of β-lactam antibiotics | |
| CN106749235A (en) | The preparation method of poly-substituted quinoline and azole derivatives | |
| CN101293891B (en) | Method for preparing ceftazidime midbody | |
| CN106350566A (en) | Enzymatic technology for compounding cefquinome sulfate | |
| JP2007238596A (en) | Direct process for forming amino acid dihydrochloride | |
| GB2137998A (en) | Benzothienyl cephalosporin antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190201 Address after: 050015 388 East Heping Road, Shijiazhuang, Hebei Applicant after: Huabei Pharmaceutical Co., Ltd. Address before: 052165 No. 98 Hainan Road, Shijiazhuang Economic and Technological Development Zone, Hebei Province Applicant before: NCPC Hebei Huamin Pharma Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191218 Address after: 300073 Tianjin City, Nankai District Wei Jin Road No. 92 Applicant after: Tianjin University Applicant after: Huabei Pharmaceutical Co., Ltd. Address before: 050015 No. 388 Heping East Road, Hebei, Shijiazhuang Applicant before: Huabei Pharmaceutical Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |